Any current/future new fundraising through debt or equity?

There is no specific mention of any current fundraising through debt or equity in the transcript. The company has term loans which lead to foreign currency losses, but no new debt fundraising is mentioned. Capex for dedicated blocks and expansions is being self-funded primarily through cash flows from operations, especially the Xanthine business. The company is undertaking significant capex (~Rs.400 Crores planned for the current year) mainly from internal accruals rather than raising new external funds. Future capex is expected to be more brownfield with lower intensity and the balance sheet

Any current/future capex/capital investment/strategic investment?

Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex. Capex for dedicated manufacturing block is included but the exact amount is still being finalized. Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up. Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters. S

Future growth expectations in sales/revenue/volumes?

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth. Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth. API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues. Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to reven

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance of 15%-18% CAGR over the next 3-4 years. EBITDA margin guidance maintained at 15%-18% over the same period. EBITDA growth expected to materialize meaningfully from Q1 FY2027 onwards as recent capex ramps up, with full contribution taking about a year. CDMO segment expected to grow 40%-50% in FY2027, driving higher revenue. Xanthine segment anticipated to reach Rs.1000 Crores revenue in FY2027, surpassing FY2025 levels. API/intermediates segment expected to recover and surpass FY2025 revenue levels (~Rs.700 Crores). Capex intensity to reduce from FY2028 as major greenfie

Current/ Expected Orderbook/ Pending Orders?

The company currently has 21 active CDMO customers, a number steady over the last five quarters. Engagements with these customers are ongoing for newer projects, indicating pipeline development. In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now. The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders. Capex decisions for custom-built facilities are based on sensible forecasts from customers. Large pro

IN US

Sale is live|00:00:00left today

Aarti Pharmalabs LtdQ1 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹691P/E: 29.9Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years.
→CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth.
→Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth.
→API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues.
→Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards.
→Working capital needs may increase due to upfront inventory buildup for large customer projects with no advance payments.
→Revenue adjustments due to foreign exchange fluctuations are expected but overall growth trajectory remains positive.

Margin guidance

Category 3

→Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
→EBITDA margin guidance maintained at 15%-18% over the same period.
→EBITDA growth expected to materialize meaningfully from Q1 FY2027 onwards as recent capex ramps up, with full contribution taking about a year.
→CDMO segment expected to grow 40%-50% in FY2027, driving higher revenue.
→Xanthine segment anticipated to reach Rs.1000 Crores revenue in FY2027, surpassing FY2025 levels.
→API/intermediates segment expected to recover and surpass FY2025 revenue levels (~Rs.700 Crores).
→Capex intensity to reduce from FY2028 as major greenfield projects complete; future expansions to be brownfield, enabling faster ramp-up and better capital efficiency.
→EPS growth aligned with revenue and margin expansion, though exact figures not explicitly provided.
→Foreign exchange losses excluded from EBITDA guidance.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any current fundraising through debt or equity in the transcript.
→The company has term loans which lead to foreign currency losses, but no new debt fundraising is mentioned.
→Capex for dedicated blocks and expansions is being self-funded primarily through cash flows from operations, especially the Xanthine business.
→The company is undertaking significant capex (~Rs.400 Crores planned for the current year) mainly from internal accruals rather than raising new external funds.
→Future capex is expected to be more brownfield with lower intensity and the balance sheet strength is emphasized as a factor helping in CDMO partnerships.
→Rashesh Gogri indicated capex decisions are backed by customer commitments and forward-looking project visibility, suggesting controlled and funded expansion rather than raising fresh capital.

Order book

→The company currently has 21 active CDMO customers, a number steady over the last five quarters.
→Engagements with these customers are ongoing for newer projects, indicating pipeline development.
→In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now.
→The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders.
→Capex decisions for custom-built facilities are based on sensible forecasts from customers.
→Large projects tend to have one or two deliveries per year, leading to inventory buildup before delivery.
→Customers do not typically provide advance payments, so inventory financing is done by the company.
→Overall, the inquiry pipeline is improving compared to the slowdown in the prior year.

Capex plans

Yes

→Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
→Capex for dedicated manufacturing block is included but the exact amount is still being finalized.
→Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up.
→Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters.
→Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027.
→Preliminary design and planning of a dedicated manufacturing block tailored to specific projects; completion expected approximately 12 months after construction begins.
→Investment in R&D for peptides and oligonucleotides with long-term potential but no immediate results expected.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio